Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Intrexon Files For IPO Of Up To $125 Mln

RELATED NEWS
Trade XON now with 

Biotechnology company Intrexon Corp. has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $125 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Germantown, Maryland based company plans to list on the New York Stock Exchange under the ticker symbol XON.

The company said in a preliminary prospectus that it plans to use the proceeds to fund continued investment in research and development platforms and its business development efforts.

Intrexon is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems

Intrexon, which was founded in 1998, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.

J.P. Morgan and Barclays are the joint bookrunners on the deal.

Click here to receive FREE breaking news email alerts for Intrexon Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.